Skip to main content
SpringerLink
Log in

HPV-Test ergänzend zum Pap-Test?

Zervixkarzinomscreening: Das ändert sich 2018

  • Gynäkoonkologie
  • Fortbildung
  • Published:
Im Focus Onkologie Aims and scope

Obwohl das Screening auf Gebärmutterhalskrebs die Inzidenz der Erkrankung bereits deutlich gesenkt hat, gibt es aufgrund neuer Erkenntnisse noch Optimierungsbedarf. Deshalb wird es im Laufe diesen Jahres Neuerungen beim Screening geben.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Robert Koch Institut. 2016; http://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Gebaermutterhalskrebs/gebaermutterhalskrebs_node.html.

  2. McCrory D, Matchar D. Evaluation of cervical cytology — systematic review. Agency for Health Care Research and Quality (AHRQ). 1999; www.ahrq.gov.

  3. Petry KU et al. Annual Papanicolaou screening for 5 years among human papillomavirus-negative women. BMC Cancer. 2013; 13:379.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Bulkmans NWJ et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370(9601):1764–72.

    Article  CAS  PubMed  Google Scholar 

  5. Ronco G et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249–57.

    Article  CAS  PubMed  Google Scholar 

  6. Anttila A et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme, BMJ. 2010;340:c1804.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mayrand MH et al. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579–88.

    Article  CAS  PubMed  Google Scholar 

  8. Walboomers JM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.

    Article  CAS  Google Scholar 

  9. Schiffman M et al. Human papillomavirus and cervical cancer. Lancet. 2007; 370(9590):890–907.

    Article  CAS  PubMed  Google Scholar 

  10. Clifford G et al. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006;24(Suppl 3):S3/26–34.

    Google Scholar 

  11. Luhn P et al. The role of co-factors in the progression from human papillomavirus infection to cervical cancer. Gynecol Oncol. 2013;128(2):265–70.

    Article  CAS  PubMed  Google Scholar 

  12. Moreno V et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002;359(9312):1085–92.

    Article  CAS  PubMed  Google Scholar 

  13. Cuzick J et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095–101.

    Article  CAS  PubMed  Google Scholar 

  14. Moscicki AB et al. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24(Suppl 3):S3/42–51.

    Google Scholar 

  15. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12(2):186–92.

    Article  CAS  PubMed  Google Scholar 

  16. Mühlhauser I, Filz M. Screening auf Zervixkarzinom: Informationen zur Beratung von Frauen. Arznei-telegramm 2008;39(3): 29–38.

    Google Scholar 

  17. IQWIG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Rapid Report S13-03: Nutzenbewertung eines HPVTests im Primärscreening des Zervixkarzinoms. 2014

  18. Gemeinsamer Bundesausschuss (2016) www.g-ba.de/downloads/39-261-2713/2016-09-15_Aenderung_Beauftragung-IQWiG_Einladung_Zervixkarzinom-Screening_vom-2015-03-19.pdf.

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Campus Großhadern, Klinikum der Universität München, Marchioninistraße 15, 81377, München, Deutschland

    Teresa Starrach

  2. http://www.springermedizin.de

    Julia Gallwas,  Sven Mahner &  Christian Dannecker

Authors
  1. Teresa Starrach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia Gallwas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sven Mahner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christian Dannecker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Teresa Starrach.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Starrach, T., Gallwas, J., Mahner, S. et al. Zervixkarzinomscreening: Das ändert sich 2018. Im Focus Onkologie 21, 36–38 (2018). https://doi.org/10.1007/s15015-018-3965-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-018-3965-3

Search

Navigation